New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2013
08:04 EDTNAVBNavidea completes study of radiopharmaceutical NAV4694
Navidea Biopharmaceuticals announced the completion of a study of its novel radiopharmaceutical NAV4694 as a biomarker for visual detection and quantification of cerebral b-amyloid in diagnosing Alzheimer's disease, or AD. The study was designed and conducted by Navidea's partner, AstraZeneca, to assess the effects of various mass amounts of AZD4694, or NAV4694, on safety and the efficacy of Positron Emission Tomography scanning in subjects with AD and in healthy volunteers. Evaluations were completed on the effects of two mass doses of the radioligand on binding parameters and overall image quality. These endpoints are typical and important requirements of drug registration dossiers filed with regulatory authorities for approval of diagnostic agents.
News For NAVB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 3, 2015
07:32 EDTNAVBNavidea awarded $1.8M grant for evaluation of Manocept agent in Kaposi's Sarcoma
Subscribe for More Information
September 2, 2015
07:33 EDTNAVBNavidea announces dual listing on Tel Aviv Stock Exchange
Navidea Biopharmaceuticals announced that the Tel Aviv Stock Exchange has approved the new listing of Navidea's common stock on the TASE beginning on Tuesday, September 8 under the ticker symbol NAVB. The company's common stock will be listed on both the NYSE MKT in the United States and the TASE in Israel. The company also announced that, based upon Navidea's current market capitalization, it expects its shares to be subject to inclusion in five TASE equity indexes.
07:27 EDTNAVBSidoti to hold a conference
2015 Sidoti Emerging Growth Conference is being held in New York on September 2.
August 24, 2015
07:32 EDTNAVBNavidea to register shares for dual listing on TASE
Navidea Biopharmaceuticals announced that it has filed an application for registration of shares of its common stock for dual listing on the Tel-Aviv Stock Exchange, or TASE. Dual listing on the TASE is allowed in the U.S. and Israel without any additional regulatory requirements for companies whose shares are listed on certain accredited stock exchanges outside of Israel, including the NYSE MKT.
August 20, 2015
07:31 EDTNAVBNavidea reports publication of Lymphoseek comparative results in pain study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use